The management of antithrombotic agents for patients undergoing
... This guideline may be revised as necessary to account for changes in technology, new data, or other aspects of clinical practice. The recommendations were based on reviewed studies and were graded on the strength of the supporting evidence (Table 1).1 This guideline is intended to be an educational ...
... This guideline may be revised as necessary to account for changes in technology, new data, or other aspects of clinical practice. The recommendations were based on reviewed studies and were graded on the strength of the supporting evidence (Table 1).1 This guideline is intended to be an educational ...
Torsade de pointes: the clinical considerations
... The pathophysiological differences between the congenital and acquired forms of torsade de pointes attribute to certain apparent differences in the treatment [44]. Immediate administration of intravenous magnesium sulfate is indicated as the first line therapy for long QT interval related ventricula ...
... The pathophysiological differences between the congenital and acquired forms of torsade de pointes attribute to certain apparent differences in the treatment [44]. Immediate administration of intravenous magnesium sulfate is indicated as the first line therapy for long QT interval related ventricula ...
Accuracy of the Electrocardiograph in Detecting Cardiac Left
... being aortic stenosis [11,12]. Aortic stenosis refers to a narrowing of the aortic valve, resulting in greater resistance (by Laplace’s law) faced by the left ventricle. Over time, this can translate into a maladaptive burden and an increased afterload upon the left ventricle, leading to the develop ...
... being aortic stenosis [11,12]. Aortic stenosis refers to a narrowing of the aortic valve, resulting in greater resistance (by Laplace’s law) faced by the left ventricle. Over time, this can translate into a maladaptive burden and an increased afterload upon the left ventricle, leading to the develop ...
Twenty-five years` experience of modified Lecompte procedure for
... At last follow-up, 43 survivors (97.7%) are in New York Heart Association (NYHA) class I, and 1 survivor (2.3%) is in NYHA class II. Only 6 survivors (13.6%) were taking medications, and 38 survivors (86.4%) do not need any medication. Cardiopulmonary exercise test was performed on 20 patients (45.5 ...
... At last follow-up, 43 survivors (97.7%) are in New York Heart Association (NYHA) class I, and 1 survivor (2.3%) is in NYHA class II. Only 6 survivors (13.6%) were taking medications, and 38 survivors (86.4%) do not need any medication. Cardiopulmonary exercise test was performed on 20 patients (45.5 ...
RR interval variation, the QT interval index and risk of primary
... added the product term QTIRRV to a model already containing QTI and RRV, thereby permitting risk estimation at several combinations of these continuous variables. We calculated Rothman’s synergy index for models including product terms. In the absence of a statistically significant multiplicative i ...
... added the product term QTIRRV to a model already containing QTI and RRV, thereby permitting risk estimation at several combinations of these continuous variables. We calculated Rothman’s synergy index for models including product terms. In the absence of a statistically significant multiplicative i ...
AHA Scientific Statement
... products were discussed, raising concerns regarding their cardiac safety. Long-term safety trials and targeted cardio- ...
... products were discussed, raising concerns regarding their cardiac safety. Long-term safety trials and targeted cardio- ...
Transcatheter Therapies for Mitral Regurgitation
... Transcatheter aortic valve replacement (TAVR) has transformed the care of patients with aortic stenosis. The dissemination of this technology after its approval in the United States in the wake of a pivotal randomized trial (1,2) has thus far proceeded in a thoughtful and circumspect manner, guided ...
... Transcatheter aortic valve replacement (TAVR) has transformed the care of patients with aortic stenosis. The dissemination of this technology after its approval in the United States in the wake of a pivotal randomized trial (1,2) has thus far proceeded in a thoughtful and circumspect manner, guided ...
ESC Guidelines for the diagnosis and treatment
... Associations: European Association for Cardiovascular Prevention & Rehabilitation (EACPR), European Association of Echocardiography (EAE), European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) Working Groups: Acute Cardiac Care, Cardiovas ...
... Associations: European Association for Cardiovascular Prevention & Rehabilitation (EACPR), European Association of Echocardiography (EAE), European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) Working Groups: Acute Cardiac Care, Cardiovas ...
ACC Heart Failure Guideline Slide Set
... Patients with LVEF less than or equal to 35%, sinus rhythm, and NYHA functional class III or ambulatory class IV symptoms despite recommended, optimal medical therapy and who have cardiac dyssynchrony, which is currently defined as a QRS duration greater than or equal to 0.12 seconds, should receive ...
... Patients with LVEF less than or equal to 35%, sinus rhythm, and NYHA functional class III or ambulatory class IV symptoms despite recommended, optimal medical therapy and who have cardiac dyssynchrony, which is currently defined as a QRS duration greater than or equal to 0.12 seconds, should receive ...
Response of recurrent sustained ventricular tachycardia to verapamil
... the tachycardia, showed that the cycle length was 450 ms (rate: 133 beats/nun). No His potential was present before the QRS complex of the tachycardia; sinus capture beats were preceded by a His potential with an HV interval of 50 ms. During right atrial pacing at a rate of 143 beats/min, fusion bea ...
... the tachycardia, showed that the cycle length was 450 ms (rate: 133 beats/nun). No His potential was present before the QRS complex of the tachycardia; sinus capture beats were preceded by a His potential with an HV interval of 50 ms. During right atrial pacing at a rate of 143 beats/min, fusion bea ...
ESC Guidelines - Dansk Cardiologisk Selskab
... Associations: European Association for Cardiovascular Prevention & Rehabilitation (EACPR), European Association of Echocardiography (EAE), European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) Working Groups: Acute Cardiac Care, Cardiovas ...
... Associations: European Association for Cardiovascular Prevention & Rehabilitation (EACPR), European Association of Echocardiography (EAE), European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) Working Groups: Acute Cardiac Care, Cardiovas ...
ACC Heart Failure Guideline Slide Set
... Patients with LVEF less than or equal to 35%, sinus rhythm, and NYHA functional class III or ambulatory class IV symptoms despite recommended, optimal medical therapy and who have cardiac dyssynchrony, which is currently defined as a QRS duration greater than or equal to 0.12 seconds, should receive ...
... Patients with LVEF less than or equal to 35%, sinus rhythm, and NYHA functional class III or ambulatory class IV symptoms despite recommended, optimal medical therapy and who have cardiac dyssynchrony, which is currently defined as a QRS duration greater than or equal to 0.12 seconds, should receive ...
- David Winston, RH
... elevated. This may be acute, caused by pain, anxiety or exertion, or a chronic condition. Chronic hypertension is a major risk factor for heart disease, peripheral vascular disease and stroke. Hypertension is usually classified as either primary (essential) hypertension or secondary hypertension. Ap ...
... elevated. This may be acute, caused by pain, anxiety or exertion, or a chronic condition. Chronic hypertension is a major risk factor for heart disease, peripheral vascular disease and stroke. Hypertension is usually classified as either primary (essential) hypertension or secondary hypertension. Ap ...
Heart sound analysis for symptom detection and computer
... Comparing the normal and abnormal S2 transfer functions, however, there are clear differences. There are two pronounced additional peaks in the case with coarctation, together with shifts in the locations and relative amplitudes of the peaks observed in the normal case. Establishing a correlation bet ...
... Comparing the normal and abnormal S2 transfer functions, however, there are clear differences. There are two pronounced additional peaks in the case with coarctation, together with shifts in the locations and relative amplitudes of the peaks observed in the normal case. Establishing a correlation bet ...
The Heart_ Pressure-Propulsion Pump or Organ of Impedance?
... cardiac output largely was unaffected by the activity of the heart.28 For example, artificial pacing of the heart at rates up to 4 times above baseline in animals29 and humans30,31 did not cause an increase in CO. Similarly, experiments on dogs, in which the right heart was replaced by a bypass pump, ...
... cardiac output largely was unaffected by the activity of the heart.28 For example, artificial pacing of the heart at rates up to 4 times above baseline in animals29 and humans30,31 did not cause an increase in CO. Similarly, experiments on dogs, in which the right heart was replaced by a bypass pump, ...
Transseptal catheterization via right subclavian vein
... and may also prevent the passage of the transseptal needle through the pelvis. In some patients the tension of the needle on the iliac veins and inferior vena cava may cause great pain and prevent its advancement or manipulation. With massive right atrial enlargement usually due to severe tricuspid ...
... and may also prevent the passage of the transseptal needle through the pelvis. In some patients the tension of the needle on the iliac veins and inferior vena cava may cause great pain and prevent its advancement or manipulation. With massive right atrial enlargement usually due to severe tricuspid ...
Paroxysmal atrial fibrillation
... incidence of stroke in the two groups (13 versus 17 percent) for a yearly incidence of 2.5 percent and 2.8 percent, respectively [38]. A similar lack of difference in embolic risk was noted in a pooled analysis from the five randomized control trials of anticoagulation in AF [39]. Furthermore, a sub ...
... incidence of stroke in the two groups (13 versus 17 percent) for a yearly incidence of 2.5 percent and 2.8 percent, respectively [38]. A similar lack of difference in embolic risk was noted in a pooled analysis from the five randomized control trials of anticoagulation in AF [39]. Furthermore, a sub ...
Total-Anomalous-Pulmonary-Venous
... for complete repair of Total anomalous pulmonary venous connection. TAPVC is a rare congenital heart defect 1,2 left untreated 80% of the patients die in first year of life.6 However it is not unusual to find an occasional patient surviving into adulthood especially in a developing country where ant ...
... for complete repair of Total anomalous pulmonary venous connection. TAPVC is a rare congenital heart defect 1,2 left untreated 80% of the patients die in first year of life.6 However it is not unusual to find an occasional patient surviving into adulthood especially in a developing country where ant ...
MCV/Q, Medical College of Virginia Quarterly, Vol. 15 No. 2
... was present. Forty-three patients (1 2%) had left main-vessel disease , 83 (23%) had single-vessel , 11 5 (32%) double-vessel, and 119 (33%) triple-vessel disease. One hundred and ninetyfour patients (54%) had abnormal ventricular function and in 84 (23%) it was considered severe. Eighty-four (23%) ...
... was present. Forty-three patients (1 2%) had left main-vessel disease , 83 (23%) had single-vessel , 11 5 (32%) double-vessel, and 119 (33%) triple-vessel disease. One hundred and ninetyfour patients (54%) had abnormal ventricular function and in 84 (23%) it was considered severe. Eighty-four (23%) ...
Pulmonary Atresia and Intact Ventricular Septum
... All of the following can present with paucity of RV forces, and LV dominance/LVH on EKG, except? (A) Pulmonary atresia and intact ventricular septum (B) Tricuspid atresia (C) Double-inlet left ventricle ...
... All of the following can present with paucity of RV forces, and LV dominance/LVH on EKG, except? (A) Pulmonary atresia and intact ventricular septum (B) Tricuspid atresia (C) Double-inlet left ventricle ...
Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics CLINICAL FORUM
... The decision to list a patient for OLT incorporates an estimate of their expected intermediate-term survival, e.g. over the next 2 yrs [5]. As with many forms of interstitial lung disease, predicting survival is difficult given both the variable EUROPEAN RESPIRATORY JOURNAL ...
... The decision to list a patient for OLT incorporates an estimate of their expected intermediate-term survival, e.g. over the next 2 yrs [5]. As with many forms of interstitial lung disease, predicting survival is difficult given both the variable EUROPEAN RESPIRATORY JOURNAL ...
Cardiac Arrhythmias in thalassaemia
... Tachycardia – ventricular (VT) • Ventricular tachycardia (VT) or broad complex tachycardia This is a medical emergency ...
... Tachycardia – ventricular (VT) • Ventricular tachycardia (VT) or broad complex tachycardia This is a medical emergency ...
Effect of dual-chamber pacing on systolic and diastolic
... from the let, ventricular inflow region and the ascending aorta (2,14-16). Transseptal catheterization was thus performed on all patients with a Brockenbrough needle and an 8F Mullins sheath. The sheath was initially placed in the inflow region of the left ventricle, and 21; and 3F high fidelity man ...
... from the let, ventricular inflow region and the ascending aorta (2,14-16). Transseptal catheterization was thus performed on all patients with a Brockenbrough needle and an 8F Mullins sheath. The sheath was initially placed in the inflow region of the left ventricle, and 21; and 3F high fidelity man ...
Ventricular Septal Rupture After Acute Myocardial Infarction
... branches of the left anterior descending coronary artery, the posterior descending branch of the right coronary artery, or the circumflex artery when it is dominant. VSR has equal frequency in anterior and non-anterior infarctions.7 Anterior MI is associated with rupture of the apical septum, in inf ...
... branches of the left anterior descending coronary artery, the posterior descending branch of the right coronary artery, or the circumflex artery when it is dominant. VSR has equal frequency in anterior and non-anterior infarctions.7 Anterior MI is associated with rupture of the apical septum, in inf ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.